Clinical Trials

Non-Muscle Invasive Bladder Neoplasms

NCT06834074 2026-05-14

NVL-655-EAP

Carcinoma, Non-Small-Cell Lung

NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Sarcoma

Desmoid Tumors

NCT06915766 2026-05-08

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT07573215 2026-05-07

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Gastrointestinal

Pancreatic Neoplasms

NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Neoplasms

NCT07535359 2026-05-06

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT06761976 2026-05-05

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Neoplasms

NCT07536815 2026-04-27

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Breast

Triple Negative Breast Neoplasms

NCT05593185 2026-04-24

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Leukemia, Lymphoma

NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Dermatologic

Melanoma

NCT04085653 2026-04-14

Managed Access Programs for BYL719, Alpelisib

Breast

Breast Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Breast

Breast Neoplasms

NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07502716 2026-03-31

Compassionate Use of Ubamatamab

Sarcoma

NCT07497984 2026-03-27

ITM11 Expanded Access Program

CNS

Meningioma

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT06799221 2026-02-27

Expanded Access Program for OOS Obe-cel

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06797362 2026-02-17

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Carcinoma, Non-Small-Cell Lung

NCT05346835 2026-02-13

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT06617572 2026-02-09

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05982873 2026-02-06

Expanded Access to Telisotuzumab Adizutecan

Other solid neoplasm

Solid Tumors

NCT03123029 2026-01-30

Expanded Access to Venetoclax

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07310277 2026-01-29

Expanded Access to ABBV-706

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06910137 2026-01-08

An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04771078 2025-12-12

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Plasma cell

Multiple Myeloma

NCT04400591 2025-12-11

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Lymphoma, Large B-Cell, Diffuse

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05776160 2025-12-01

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Lymphoma, Follicular

NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Neoplasms

NCT06048081 2025-09-10

Early Access Program for Zolbetuximab

Adenocarcinoma

NCT06872489 2025-07-23

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

CNSGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neuroblastoma, Pancreatic Neoplasms, Recurrence

NCT06090331 2025-07-08

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Carcinoma, Renal Cell

NCT06362590 2025-06-17

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Neoplasm Metastasis, Prostatic Neoplasms

NCT04809233 2025-06-04

Expanded Access to Tipifarnib

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT05738538 2025-06-04

Expanded Access to Ziftomenib

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06980506 2025-05-22

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Neoplasms

NCT06980519 2025-05-22

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Neoplasms

NCT06743100 2025-04-02

18F-Floretyrosine Expanded Access Program